Cargando…

An Innovative Non-Linear Prediction Model for Clinical Benefit in Women with Newly Diagnosed Breast Cancer Using Baseline FDG-PET/CT and Clinical Data

SIMPLE SUMMARY: This study aimed to develop an innovative non-linear statistical model to predict clinical benefit in women with newly diagnosed breast cancer. A logistic generalized additive model was chosen as an innovative statistical approach, as opposed to conventional techniques. Clinical data...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kudura, Ken, Ritz, Nando, Templeton, Arnoud J., Kutzker, Tim, Hoffmann, Martin H. K., Antwi, Kwadwo, Zwahlen, Daniel R., Kreissl, Michael C., Foerster, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670812/ https://www.ncbi.nlm.nih.gov/pubmed/38001736 http://dx.doi.org/10.3390/cancers15225476

Ejemplares similares

Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors
por: Kudura, Ken, et al.
Publicado: (2022)

Additional Primary Tumors Detected Incidentally on FDG PET/CT at Staging in Patients with First Diagnosis of NSCLC: Frequency, Impact on Patient Management and Survival
por: Kudura, Ken, et al.
Publicado: (2023)

Predictive Value of Total Metabolic Tumor Burden Prior to Treatment in NSCLC Patients Treated with Immune Checkpoint Inhibition
por: Kudura, Ken, et al.
Publicado: (2023)

Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients
por: Kudura, Ken, et al.
Publicado: (2021)

Hypermetabolic Ipsilateral Supraclavicular and Axillary Lymphadenopathy: Optimal Time Point for Performing an (18)F-FDG PET/CT after COVID-19 Vaccination
por: Antwi, Kwadwo, et al.
Publicado: (2022)

Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients
por: Kudura, Ken, et al.
Publicado: (2021)

Correction: Kudura et al. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. Cancers 2021, 13, 3830
por: Kudura, Ken, et al.
Publicado: (2022)

Clinical value of baseline (18)F-FDG PET/CT in soft tissue sarcomas
por: Reyes Marlés, Rafael Hernando, et al.
Publicado: (2021)

On the Added Value of Baseline FDG-PET in Malignant Lymphoma
por: Quarles van Ufford, Henriette, et al.
Publicado: (2009)

Innovative imaging of insulinoma: the end of sampling? A review
por: Christ, Emanuel, et al.
Publicado: (2020)

Can Dynamic Whole-Body FDG PET Imaging Differentiate between Malignant and Inflammatory Lesions?
por: Skawran, Stephan, et al.
Publicado: (2022)

Monitoring scanner calibration using the image-derived arterial blood SUV in whole-body FDG-PET
por: Maus, Jens, et al.
Publicado: (2018)

Automated quantification of baseline imaging PET metrics on FDG PET/CT images of pediatric Hodgkin lymphoma patients
por: Weisman, Amy J., et al.
Publicado: (2020)

Convolutional Neural Networks Promising in Lung Cancer T-Parameter Assessment on Baseline FDG-PET/CT
por: Kirienko, Margarita, et al.
Publicado: (2018)

Prognostic Values of Baseline (18)F-FDG PET/CT in Patients with Peripheral T-Cell Lymphoma
por: Zhou, Yeye, et al.
Publicado: (2020)

Diagnostic value of baseline (18)FDG PET/CT skeletal textural features in follicular lymphoma
por: Faudemer, Julie, et al.
Publicado: (2021)

The impact of baseline (18)F-FDG PET-CT on the management and outcome of patients with gastric cancer
por: Foley, Kieran G, et al.
Publicado: (2022)

Detection of bone marrow involvement with FDG PET/CT in patients with newly diagnosed lymphoma
por: Özpolat, H. Tahsin, et al.
Publicado: (2018)

Inflammatory Blood Parameters as Biomarkers for Response to Immune Checkpoint Inhibition in Metastatic Melanoma Patients
por: Kudura, Ken, et al.
Publicado: (2022)

Sex-Related Differences in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition
por: Kudura, Ken, et al.
Publicado: (2022)

Clinical Applications of FDG PET and PET/CT in Head and Neck Cancer
por: Al-Ibraheem, Akram, et al.
Publicado: (2009)

Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials
por: Michaud-Robert, Anne-Victoire, et al.
Publicado: (2020)

The Incremental Prognostic Value of Baseline (18)F-FDG PET/CT Imaging in Angioimmunoblastic T-Cell Lymphoma
por: Wang, Hui, et al.
Publicado: (2020)

When SUV Matters: FDG PET/CT at Baseline Correlates with Survival in Soft Tissue and Ewing Sarcoma
por: Hack, Ruben I., et al.
Publicado: (2021)

Effects of cigarette smoking on metabolic activity of lung cancer on baseline (18)F-FDG PET/CT
por: Jiang, Maoqing, et al.
Publicado: (2022)

Quantification of FDG-PET/CT with delayed imaging in patients with newly diagnosed recurrent breast cancer
por: Baun, Christina, et al.
Publicado: (2018)

Clinical, FDG and amyloid PET imaging in posterior cortical atrophy
por: Singh, Tarun D., et al.
Publicado: (2015)

Whole-body parametric [(18)F]-FDG PET/CT improves interpretation of a distant lesion as venous embolus in a lung cancer patient
por: Messerli, Michael, et al.
Publicado: (2021)

Conventional Imaging, MRI and (18)F-FDG PET/MRI for N and M Staging in Patients with Newly Diagnosed Breast Cancer
por: Morawitz, Janna, et al.
Publicado: (2023)

Prognostic values of baseline, interim and end-of therapy (18)F-FDG PET/CT in patients with follicular lymphoma
por: Zhou, Yeye, et al.
Publicado: (2019)

Baseline SUVmax of (18)F-FDG PET-CT indicates prognosis of extranodal natural killer/T-cell lymphoma
por: Xia, Xianwu, et al.
Publicado: (2020)

The prognostic role of 18F-FDG PET/CT baseline quantitative metabolic parameters in peripheral T-cell lymphoma
por: Xia, Jun, et al.
Publicado: (2019)

Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma
por: Liberini, Virginia, et al.
Publicado: (2021)

Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments
por: Jemaa, S., et al.
Publicado: (2022)

A zero-dose synthetic baseline for the personalized analysis of [(18)F]FDG-PET: Application in Alzheimer’s disease
por: Hinge, Christian, et al.
Publicado: (2022)

Prediction of pathological response after neoadjuvant chemotherapy using baseline FDG PET heterogeneity features in breast cancer
por: Oliveira, Carla, et al.
Publicado: (2023)

Baseline (18)F-FDG PET/CT radiomics for prognosis prediction in diffuse large B cell lymphoma
por: Jing, Fenglian, et al.
Publicado: (2023)

Comparison of nodal staging between CT, MRI, and [(18)F]-FDG PET/MRI in patients with newly diagnosed breast cancer
por: Morawitz, Janna, et al.
Publicado: (2021)

Improved detection of in-transit metastases of malignant melanoma with BSREM reconstruction in digital [(18)F]FDG PET/CT
por: Liberini, Virginia, et al.
Publicado: (2021)

Considerations for the clinical development of immuno-oncology agents in cancer
por: Pandiella, Atanasio, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tlgstbdu1jq9d4jmacju6peema